← Leaderboards
Paul Gregor
Gismo Therapeutics, Inc.
$5,661,712
Attributed
$5,661,712
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2013–24$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,661,712 · 4
By mechanism
R44$4,855,452 · 1
R43$806,260 · 3
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposToxic EffectPharmaceutical PreparationsSafetyPolysulfated GlycosaminoglycanDrug KineticsIn VitroGlycosaminoglycansSmall MoleculeAmyloidSeriesRodentHeparitin SulfatePre-ClinicalOralPlasmaBrainPropertyToxicologyProgramsBiological AvailabilityMouse ModelAmyloid Beta-ProteinLead
Grant awards (9)
Amyloid-Beta and Tau/Glycosaminoglycan Dual Inhibitor for Alzheimer's Disease$1,192,768
R44 · FY2024 · AG · contact PI
Amyloid-Beta and Tau/Glycosaminoglycan Dual Inhibitor for Alzheimer's Disease$792,857
R44 · FY2023 · AG · contact PI
Amyloid-Beta and Tau/Glycosaminoglycan Dual Inhibitor for Alzheimer's Disease$983,932
R44 · FY2022 · AG · contact PI
Glycosaminoglycan-Interacting Small Molecule (GISMO) as Alzheimer's Therapeutics$952,480
R44 · FY2018 · AG · contact PI
Glycosaminoglycan-Interacting Small Molecule (GISMO) as Alzheimer's Therapeutics$933,415
R44 · FY2017 · AG · contact PI
Glycosaminoglycan-Interacting Small Molecule (GISMO) as Parkinson's Therapeutic$142,188
R43 · FY2017 · NS · contact PI
Glycosaminoglycan-Interacting Small Molecule (GISMO) as Parkinson's Therapeutic$241,938
R43 · FY2016 · NS · contact PI
Glycosaminoglycan-Cytokine Inhibitors for Arthritis Therapy$224,997
R43 · FY2015 · AR · contact PI
Glycosaminoglycan Interacting Small Molecules (GISMO) as Novel AD Therapeutics$197,137
R43 · FY2013 · AG · contact PI